Related Experiment Video
Updated: Feb 19, 2026
Experimental Human Pneumococcal Carriage
Published on: February 15, 2013
Cost-effectiveness analysis of infant pneumococcal vaccination with PHiD-CV in Korea
Xu-Hao Zhang1, Oscar Leeuwenkamp2, Kyu-Bin Oh3
1a GSK , Singapore.
Insights
The 10-valent pneumococcal NTHi protein D conjugate vaccine (PHiD-CV) offers greater cost-effectiveness and health benefits than the 13-valent pneumococcal conjugate vaccine (PCV-13) for Korea's National Immunization Program.
Area of Science:
- Vaccinology and Public Health
- Health Economics
- Infectious Disease Epidemiology
Background:
- Streptococcus pneumoniae and non-typeable Haemophilus influenzae (NTHi) cause significant disease burdens, including invasive pneumococcal diseases (IPD), pneumonia, and acute otitis media (AOM).
- Both PHiD-CV and PCV-13 are integral to Korea's National Immunization Program for infants.
- Evaluating vaccine cost-effectiveness is crucial for optimizing public health resource allocation.
Purpose of the Study:
- To compare the cost-effectiveness of the PHiD-CV 3+1 schedule against the PCV-13 schedule within Korea's National Immunization Program.
- To assess the economic and health outcome differences between PHiD-CV and PCV-13 from the Korean government's perspective.
- To inform policy decisions regarding infant vaccination strategies in Korea.
Main Methods:
- Adaptation of a published Markov model to simulate costs and health outcomes over 10 years for the 2012 birth cohort.
- Utilizing published data for epidemiology and vaccine efficacy, supplemented by Korean national insurance claims data for incidence and costs.
- Conducting sensitivity analyses to ensure the robustness and reliability of the cost-effectiveness findings.
Main Results:
- PHiD-CV is projected to prevent an additional 195,262 cases of pneumococcal and NTHi-related diseases compared to PCV-13.
- PHiD-CV demonstrated a substantially greater reduction in NTHi-related AOM and comparable reductions in IPD and community-acquired pneumonia.
- At parity pricing, PHiD-CV is estimated to yield a health gain of 844 quality-adjusted life years and cost savings of approximately $4 million USD over 10 years, with 93% of simulations favoring PHiD-CV.
Conclusions:
- PHiD-CV offers comparable prevention of IPD and community-acquired pneumonia to PCV-13, with superior effectiveness against AOM.
- Parity-priced PHiD-CV is anticipated to generate significant cost savings and health benefits for the Korean healthcare system compared to PCV-13.
- The PHiD-CV 3+1 schedule represents a dominant and cost-effective vaccination strategy for Korea's National Immunization Program.
Background:
Streptococcus pneumoniae and non-typeable Haemophilus influenzae (NTHi) can cause invasive pneumococcal diseases (IPD), pneumonia, and acute otitis media (AOM). Both the 10-valent pneumococcal NTHi protein D conjugate vaccine (PHiD-CV) and the 13-valent pneumococcal conjugate vaccine (PCV-13) are included in the National Immunization Program for infants in Korea. This study aimed to evaluate the cost-effectiveness of the 3+1 schedule of PHiD-CV versus that of PCV-13 for National Immunization Program in Korea.
Methods:
A published Markov model was adapted to evaluate the cost-effectiveness of vaccinating the 2012 birth cohort with PHiD-CV vs. PCV-13 from the Korean government perspective over 10 y. Best available published data were used for epidemiology, vaccine efficacy and disutilities. Data on incidence and direct medical costs were taken from the national insurance claims database. Sensitivity analyses were conducted to explore the robustness of the results.
Results:
PHiD-CV was projected to prevent an additional 195,262 cases of pneumococcal diseases and NTHi-related diseases vs. PCV-13, with a substantially greater reduction in NTHi-related AOM and a comparable reduction in IPD and community-acquired pneumonia. Parity-priced PHiD-CV generated a health gain of about 844 quality-adjusted life years and a total cost-saving of approximately 4 million United States Dollars (USD) over 10 y. 93% of probabilistic simulations found PHiD-CV 3+1 to be the dominant vaccine option.
Conclusion:
Compared to PCV-13, PHiD-CV was projected to provide similar prevention against IPD and community-acquired pneumonia but would prevent more cases of AOM. Parity-priced PHiD-CV was anticipated to generate substantial cost-savings and health benefits vs. PCV-13 in Korea.
More Related Videos
09:20Investigating the Effects of Probiotics on Pneumococcal Colonization Using an In Vitro Adherence Assay
Published on: April 28, 2014
11:32Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
Related Concept Videos
01:30Pneumonia III: Complications and Assessment
01:29Drug Dosing: Infants and Children
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...